Calendar

Cloudflare's Q3 consensus and growth outlook were credible, but its Oct. 30 close fell 9.54% on elevated volume, with the preceding sessions also declining. The high-volume session was a sharp down day, not accumulation; the recent price tape fails the required positive-strength check and outweighs the constructive growth backdrop.

A modest positive whisper gap ($2.94 versus $2.89 consensus) and expected revenue growth provide some support, but the stock weakened into the event and the last three observed sessions did not show a close in the top quartile or a volume surge; prior-quarter execution has been inconsistent.

EOG has a positive EPS whisper gap ($4.56 versus $4.45 consensus), recent upward EPS and revenue estimate revisions, and strong pre-event price action; reported Q2 production growth and recent earnings beats support the operating case. However, recent volume does not show a qualifying 1.5x accumulation signal, and energy earnings remain exposed to commodity-price volatility.

Lumentum’s company outlook and current consensus imply sharply higher year-over-year revenue and EPS, supported by reported AI/data-center demand and a recent run of quarterly EPS beats. The stock gained 11.2% over the five sessions through October 30 and had a strong close on October 28, but its 20-session trend remained weak, October 30’s high-volume decline and a sharp XLK selloff undermine confirmation; EPS/revenue revisions and whisper data were not independently established.

Simon had strong reported Q2 operating indicators and raised full-year FFO guidance, while shares strengthened into Oct. 30; however, the checked sources did not establish positive current-quarter EPS revisions or a credible revenue-upside signal, and recent volume did not reach the required 1.5x threshold. This is not a qualifying pre-earnings surprise setup.

Natera’s recent operating growth and the Oct. 29 close location are constructive, but the checked Zacks preview reported a sharp downward revision to Q3 EPS consensus, and no positive revenue revision/upside signal was established. The Oct. 30 high-volume selloff also weakens the setup; its total score is below the qualifying threshold.

Analyst EPS estimates have moved up over the past month and the stock advanced strongly into the event, with Oct. 30 closing near its session high; however, a revenue-upside/revision signal and a recent 1.5x volume confirmation were not established, while public consensus sources disagree on the quarter's revenue estimate.

Earnings Whispers shows a positive $1.48 whisper against $1.39 consensus, while prior company materials describe cloud migration and AI adoption momentum. However, shares fell 6.1% on October 30 as XLK fell 4.89%; no recent positive revenue revision or validated close-location/volume accumulation signal was found, so the setup does not meet the required tape confirmation.

Zacks reported a 12.23% upward 30-day EPS estimate revision and forecast revenue growth, with Con Edison’s prior-quarter release reaffirming 2026 adjusted EPS guidance. But no checked source established positive revenue revisions or enough pre-event OHLCV detail to verify close-location and volume thresholds, so the required tape-backed surprise setup is incomplete.

MCHP’s Nov. 5 after-close event is supported by its investor-relations calendar and checked consensus sources, and the company’s guidance implies recovery from a depressed cycle; however, the latest session was a high-volume sharp decline and the semiconductor ETF’s checked five-day performance was deeply negative, with no verified positive estimate revisions or revenue-upside signal.

LYV has a confirmed Nov. 5 after-close report, recent price strength, and prior-quarter operating momentum, but the checks found no documented positive estimate revision or revenue-upside signal, and the observed volume did not establish accumulation above 1.5x normal; the setup therefore does not meet the required surprise criteria.

ARM had positive recent EPS estimate revision breadth and company guidance above an earlier consensus reference, while prior company commentary described strong demand across cloud infrastructure and edge compute. The stock nevertheless fell about 10% on Oct 30 and closed well off the session high; the checked sources do not establish a recent 1.5x-volume accumulation signal. Arm IR confirms Nov 4, rather than the supplied universe's Nov 5 date.

Moderna’s date and consensus forecasts are available, but no checked source establishes positive estimate revisions or a revenue-upside signal. The business has a potentially important oncology pipeline, yet recent coverage describes a sharp sell-the-news retreat after melanoma-vaccine data; October 30 closed down 0.47%, making the current pre-event setup volatile rather than a confirmed accumulation pattern.

BAM has a rising share price, a strong Oct. 30 close, and Q2 fee-related earnings growth supported by record fundraising. Q3 consensus EPS and revenue are available, but checked sources did not establish positive EPS revisions/ESP/whisper or revenue upside against consensus, and no recent 1.5x-volume confirmation was found.

HUM’s share price was higher over the broader recent period and its Oct. 29 close was near the session high, but recent volume was below normal and checked sources did not establish positive EPS revisions or a revenue-upside signal. Its sharply reduced 2026 GAAP EPS outlook is a material caution against treating the prior-quarter beat as evidence of an impending surprise.

Vistra's company-confirmed report date and third-party estimates imply substantial year-over-year EPS and revenue growth, but estimates disagree materially ($2.18 versus $2.98 EPS), and the stock has weakened into the event with poor close locations and below-average recent volume. There is no verified positive estimate-revision or whisper signal, so the required surprise setup is absent.

Monster's investor-relations announcement states its Q3 results would be released after the close on Nov 5, conflicting with the supplied Nov 6 date. Recent shares rose over the observed short interval and the company has ongoing brand/portfolio growth, but the date conflict plus missing verified EPS consensus/revisions and revenue-upside evidence prevent qualification.